trimebutine has been researched along with Diarrhea in 8 studies
Trimebutine: Proposed spasmolytic with possible local anesthetic action used in gastrointestinal disorders.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Supportive treatment with loperamide is associated with constipation." | 9.69 | Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B). ( Doi, M; Iwasa, T; Masuda, H; Matsumoto, K; Miyoshi, Y; Niikura, N; Sagara, Y; Sakai, H; Shimomura, A; Takahashi, M; Takano, T; Tanabe, Y; Tokunaga, S; Tsurutani, J; Yoshimura, K, 2023) |
| "To observe the efficacy and adverse drug reaction of trimebutine maleate in treating patients with functional dyspepsia (FD) coexisting with diarrhea dominant irritable bowel syndrome (IBS-D)." | 9.12 | [A randomized and case-control clinical study on trimebutine maleate in treating functional dyspepsia coexisting with diarrhea-dominant irritable bowel syndrome]. ( Guo, JN; Li, HJ; Lin, YH; Yan, R; Zeng, ZY; Zhong, YQ; Zhu, J, 2007) |
| "Fenoverine acts as a synchronizer of smooth muscle in modulating the intracellular influx of calcium." | 6.78 | [Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study]. ( Baek, IH; Choi, SC; Choung, RS; Jeen, YT; Kang, SH; Kim, KO; Kim, SY; Kim, YS; Koo, JS; Koo, YS; Lee, JH; Lee, SJ; Moon, JS; Park, JJ; Park, SC, 2013) |
| " Supportive treatment with loperamide is associated with constipation." | 5.69 | Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B). ( Doi, M; Iwasa, T; Masuda, H; Matsumoto, K; Miyoshi, Y; Niikura, N; Sagara, Y; Sakai, H; Shimomura, A; Takahashi, M; Takano, T; Tanabe, Y; Tokunaga, S; Tsurutani, J; Yoshimura, K, 2023) |
| "To observe the efficacy and adverse drug reaction of trimebutine maleate in treating patients with functional dyspepsia (FD) coexisting with diarrhea dominant irritable bowel syndrome (IBS-D)." | 5.12 | [A randomized and case-control clinical study on trimebutine maleate in treating functional dyspepsia coexisting with diarrhea-dominant irritable bowel syndrome]. ( Guo, JN; Li, HJ; Lin, YH; Yan, R; Zeng, ZY; Zhong, YQ; Zhu, J, 2007) |
| "We studied effects of a novel alpha-2 adrenoceptor antagonist, YNS-15P (N-[(2R,11bS)-9-methoxy-1,3,4,6,7, 11b-hexahydro-2H-benzoquinolizin-2-yl]-N-methylmethanesulfonami de hydrochloride), on colonic propulsion stimulated by wrap-restraint stress (WRS) or bethanechol, on normal colonic propulsion and on diarrhea induced by castor oil in rats." | 3.70 | Effect of YNS-15P, a new alpha-2 adrenoceptor antagonist, on stress-stimulated colonic propulsion in rats. ( Kimura, K; Kise, M; Kyotani, Y; Niida, H; Shirouchi, Y; Tajima, K; Ueda, F; Yamamoto, O, 1998) |
| "Fenoverine acts as a synchronizer of smooth muscle in modulating the intracellular influx of calcium." | 2.78 | [Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study]. ( Baek, IH; Choi, SC; Choung, RS; Jeen, YT; Kang, SH; Kim, KO; Kim, SY; Kim, YS; Koo, JS; Koo, YS; Lee, JH; Lee, SJ; Moon, JS; Park, JJ; Park, SC, 2013) |
| "Cisapride was a potent stimulant of gastric emptying in rats, 7 times more potent than metoclopramide." | 1.28 | General pharmacology of the four gastrointestinal motility stimulants bethanechol, metoclopramide, trimebutine, and cisapride. ( Awouters, FH; Megens, AA; Niemegeers, CJ, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Makarova, AA | 2 |
| Diukova, GM | 2 |
| Ruchkina, IN | 2 |
| Romashkina, NV | 2 |
| Indejkina, LK | 2 |
| Degterev, DA | 2 |
| Dbar, SR | 2 |
| Parfenov, AI | 2 |
| Masuda, H | 1 |
| Tanabe, Y | 1 |
| Sakai, H | 1 |
| Matsumoto, K | 1 |
| Shimomura, A | 1 |
| Doi, M | 1 |
| Miyoshi, Y | 1 |
| Takahashi, M | 1 |
| Sagara, Y | 1 |
| Tokunaga, S | 1 |
| Iwasa, T | 1 |
| Niikura, N | 1 |
| Yoshimura, K | 1 |
| Takano, T | 1 |
| Tsurutani, J | 1 |
| Kang, SH | 1 |
| Jeen, YT | 1 |
| Koo, JS | 1 |
| Koo, YS | 1 |
| Kim, KO | 1 |
| Kim, YS | 1 |
| Kim, SY | 1 |
| Moon, JS | 1 |
| Park, JJ | 1 |
| Baek, IH | 1 |
| Park, SC | 1 |
| Lee, SJ | 1 |
| Lee, JH | 1 |
| Choung, RS | 1 |
| Choi, SC | 1 |
| Mearin, F | 1 |
| Zhong, YQ | 1 |
| Zhu, J | 1 |
| Guo, JN | 1 |
| Yan, R | 1 |
| Li, HJ | 1 |
| Lin, YH | 1 |
| Zeng, ZY | 1 |
| Miyata, K | 1 |
| Ito, H | 1 |
| Yamano, M | 1 |
| Hidaka, K | 1 |
| Kamato, T | 1 |
| Nishida, A | 1 |
| Yuki, H | 1 |
| Yamamoto, O | 1 |
| Niida, H | 1 |
| Tajima, K | 1 |
| Shirouchi, Y | 1 |
| Kyotani, Y | 1 |
| Ueda, F | 1 |
| Kise, M | 1 |
| Kimura, K | 1 |
| Megens, AA | 1 |
| Awouters, FH | 1 |
| Niemegeers, CJ | 1 |
1 review available for trimebutine and Diarrhea
| Article | Year |
|---|---|
[Drug treatment of irritable bowel syndrome: an unmet need].
Topics: Abdominal Pain; Analgesics; Antidepressive Agents, Tricyclic; Antidiarrheals; Carbolines; Controlled | 2007 |
4 trials available for trimebutine and Diarrhea
| Article | Year |
|---|---|
[Visceral sensitivity in diagnostics and treatment of severe irritated bowel syndrome].
Topics: Adult; Diarrhea; Duloxetine Hydrochloride; Female; Humans; Irritable Bowel Syndrome; Male; Pain; Ser | 2022 |
[Visceral sensitivity in diagnostics and treatment of severe irritated bowel syndrome].
Topics: Adult; Diarrhea; Duloxetine Hydrochloride; Female; Humans; Irritable Bowel Syndrome; Male; Pain; Ser | 2022 |
[Visceral sensitivity in diagnostics and treatment of severe irritated bowel syndrome].
Topics: Adult; Diarrhea; Duloxetine Hydrochloride; Female; Humans; Irritable Bowel Syndrome; Male; Pain; Ser | 2022 |
[Visceral sensitivity in diagnostics and treatment of severe irritated bowel syndrome].
Topics: Adult; Diarrhea; Duloxetine Hydrochloride; Female; Humans; Irritable Bowel Syndrome; Male; Pain; Ser | 2022 |
Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B).
Topics: Breast Neoplasms; Constipation; Diarrhea; Female; Humans; Loperamide; Probiotics; Quality of Life; T | 2023 |
[Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study].
Topics: Abdominal Pain; Adult; Constipation; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fe | 2013 |
[A randomized and case-control clinical study on trimebutine maleate in treating functional dyspepsia coexisting with diarrhea-dominant irritable bowel syndrome].
Topics: Adolescent; Adult; Case-Control Studies; Constipation; Diarrhea; Dyspepsia; Female; Gastrointestinal | 2007 |
3 other studies available for trimebutine and Diarrhea
| Article | Year |
|---|---|
Comparison of the effects of trimebutine and YM114 (KAE-393), a novel 5-HT3 receptor antagonist, on stress-induced defecation.
Topics: Animals; Benzimidazoles; Castor Oil; Cell Membrane; Defecation; Diarrhea; Dinoprostone; Heart Rate; | 1993 |
Effect of YNS-15P, a new alpha-2 adrenoceptor antagonist, on stress-stimulated colonic propulsion in rats.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Bethanechol; Castor | 1998 |
General pharmacology of the four gastrointestinal motility stimulants bethanechol, metoclopramide, trimebutine, and cisapride.
Topics: Animals; Apomorphine; Bethanechol Compounds; Cisapride; Conditioning, Operant; Diarrhea; Dogs; Gastr | 1991 |